Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,020,605
  • Shares Outstanding, K 160,756
  • Annual Sales, $ 441,760 K
  • Annual Income, $ -281,580 K
  • 60-Month Beta 0.61
  • Price/Sales 7.20
  • Price/Cash Flow N/A
  • Price/Book 5.61
Trade ACAD with:

Options Overview Details

View History
  • Implied Volatility 100.31%
  • Historical Volatility 79.11%
  • IV Percentile 83%
  • IV Rank 60.55%
  • IV High 140.61% on 03/09/21
  • IV Low 38.43% on 06/03/21
  • Put/Call Vol Ratio 1.26
  • Today's Volume 271
  • Volume Avg (30-Day) 2,171
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 15,387
  • Open Int (30-Day) 27,086

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.25
  • Number of Estimates 10
  • High Estimate -0.14
  • Low Estimate -0.37
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +40.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.88 +11.32%
on 10/27/21
21.88 -14.12%
on 11/09/21
+1.23 (+7.00%)
since 10/26/21
3-Month
15.68 +19.84%
on 09/14/21
21.88 -14.12%
on 11/09/21
+2.11 (+12.65%)
since 08/26/21
52-Week
15.68 +19.84%
on 09/14/21
57.34 -67.23%
on 12/21/20
-37.07 (-66.36%)
since 11/25/20

Most Recent Stories

More News
Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the national launch of Yours, Truly , a multicultural, storytelling campaign to bring greater awareness and understanding of the varied experiences...

ACAD : 18.79 (-5.01%)
ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates

ACADIA Pharmaceuticals (ACAD) posts narrower-than-expected loss for the third quarter of 2021. Revenues also beat estimates. Resultantly, its shares rise in after-hours trading.

REGN : 643.35 (-0.75%)
ENDP : 5.83 (-3.64%)
ALKS : 22.47 (-1.79%)
ACAD : 18.79 (-5.01%)
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 66.67% and 3.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ACAD : 18.79 (-5.01%)
Acadia: Q3 Earnings Snapshot

SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Monday reported a loss of $14.5 million in its third quarter.

ACAD : 18.79 (-5.01%)
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021.

ACAD : 18.79 (-5.01%)
Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) outcomes were presented at Psych...

ACAD : 18.79 (-5.01%)
Should Schwab U.S. MidCap ETF (SCHM) Be on Your Investing Radar?

Style Box ETF report for SCHM

SCHM : 79.42 (-2.56%)
AAP : 226.73 (-2.85%)
AAL : 17.75 (-8.79%)
ACAD : 18.79 (-5.01%)
IJH : 277.36 (-3.17%)
VO : 250.48 (-2.33%)
Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately. Mr. Teehan, previously...

ACAD : 18.79 (-5.01%)
Humana (HUM) to Post Q3 Earnings: What's in the Cards?

Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.

HUM : 428.49 (-1.77%)
ZTS : 219.32 (-1.73%)
ACAD : 18.79 (-5.01%)
CGC : 11.69 (-1.52%)
ACAD December 10th Options Begin Trading

Investors in Acadia Pharmaceuticals Inc saw new options become available today, for the December 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options...

ACAD : 18.79 (-5.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104...

See More

Key Turning Points

3rd Resistance Point 20.92
2nd Resistance Point 20.41
1st Resistance Point 19.60
Last Price 18.79
1st Support Level 18.28
2nd Support Level 17.77
3rd Support Level 16.96

See More

52-Week High 57.34
Fibonacci 61.8% 41.43
Fibonacci 50% 36.51
Fibonacci 38.2% 31.59
Last Price 18.79
52-Week Low 15.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar